Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 161

1.

Cost-effectiveness of vaccinating adults with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in Germany.

Jiang Y, Gauthier A, Annemans L, van der Linden M, Nicolas-Spony L, Bresse X.

Expert Rev Pharmacoecon Outcomes Res. 2012 Oct;12(5):645-60. doi: 10.1586/erp.12.54.

PMID:
23025422
2.

Cost-effectiveness of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK.

Jiang Y, Gauthier A, Keeping S, Carroll S.

Expert Rev Pharmacoecon Outcomes Res. 2014 Dec;14(6):913-27. doi: 10.1586/14737167.2014.950232.

PMID:
25189087
3.

A public health and budget impact analysis of vaccinating at-risk adults and the elderly against pneumococcal diseases in Germany.

Jiang Y, Gauthier A, Annemans L, van der Linden M, Nicolas-Spony L, Bresse X.

Expert Rev Pharmacoecon Outcomes Res. 2012 Oct;12(5):631-43. doi: 10.1586/erp.12.55.

PMID:
23025421
4.

Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine.

Smith KJ, Wateska AR, Nowalk MP, Raymund M, Nuorti JP, Zimmerman RK.

JAMA. 2012 Feb 22;307(8):804-12. doi: 10.1001/jama.2012.169.

5.

Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.

Tyo KR, Rosen MM, Zeng W, Yap M, Pwee KH, Ang LW, Shepard DS.

Vaccine. 2011 Sep 2;29(38):6686-94. doi: 10.1016/j.vaccine.2011.06.091.

PMID:
21745516
6.

Cost effectiveness analysis of heptavalent pneumococcal conjugate vaccine in Germany considering herd immunity effects.

Claes C, Reinert RR, von der Schulenburg JM.

Eur J Health Econ. 2009 Feb;10(1):25-38. doi: 10.1007/s10198-008-0098-1.

PMID:
18379830
7.

Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.

Wisløff T, Abrahamsen TG, Bergsaker MA, Løvoll Ø, Møller P, Pedersen MK, Kristiansen IS.

Vaccine. 2006 Jul 17;24(29-30):5690-9.

PMID:
16735083
8.

Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines.

Rozenbaum MH, Sanders EA, van Hoek AJ, Jansen AG, van der Ende A, van den Dobbelsteen G, Rodenburg GD, Hak E, Postma MJ.

BMJ. 2010 Jun 2;340:c2509. doi: 10.1136/bmj.c2509.

9.

Cost-effectiveness of the pneumococcal vaccine in healthy younger adults.

Pepper PV, Owens DK.

Med Decis Making. 2002 Sep-Oct;22(5 Suppl):S45-57.

PMID:
12369231
10.

Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales.

Andrews NJ, Waight PA, George RC, Slack MP, Miller E.

Vaccine. 2012 Nov 6;30(48):6802-8. doi: 10.1016/j.vaccine.2012.09.019.

PMID:
23000122
11.

The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine.

Isaacman DJ, Strutton DR, Kalpas EA, Horowicz-Mehler N, Stern LS, Casciano R, Ciuryla V.

Clin Ther. 2008 Feb;30(2):341-57. doi: 10.1016/j.clinthera.2008.02.003. Review.

PMID:
18343273
12.

Cost-effectiveness analysis of pneumococcal polysaccharide vaccination from age 60 in São Paulo State, Brazil.

Neto JT, de Araujo GT, Gagliardi A, Pinho A, Durand L, Fonseca M.

Hum Vaccin. 2011 Oct;7(10):1037-47. doi: 10.4161/hv.7.10.15987.

13.

Combination vaccine against invasive meningococcal B and pneumococcal infections: potential epidemiological and economic impact in the Netherlands.

Bos JM, Rümke HC, Welte R, Spanjaard L, van Alphen L, Postma MJ.

Pharmacoeconomics. 2006;24(2):141-53.

PMID:
16460135
14.

Cost-benefit and cost-effectiveness of the incorporation of the pneumococcal 7-valent conjugated vaccine in the routine vaccination schedule of Catalonia (Spain).

Navas E, Salleras L, Gisbert R, Domínguez A, Timoner E, Ibáñez D, Prat A.

Vaccine. 2005 Mar 18;23(17-18):2342-8.

PMID:
15755625
15.
16.

Cost-effectiveness of 13-valent pneumococcal conjugate vaccine in Switzerland.

Blank PR, Szucs TD.

Vaccine. 2012 Jun 13;30(28):4267-75. doi: 10.1016/j.vaccine.2012.04.028.

PMID:
22521287
17.

Pharmacoeconomic assessment of implementing a universal PCV-13 vaccination programme in the Valencian public health system (Spain).

Díez-Domingo J, Ridao-López M, Gutiérrez-Gimeno MV, Puig-Barberá J, Lluch-Rodrigo JA, Pastor-Villalba E.

Vaccine. 2011 Dec 6;29(52):9640-8. doi: 10.1016/j.vaccine.2011.10.038.

PMID:
22027484
18.

Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged > or =65 years in the Netherlands.

Rozenbaum MH, Hak E, van der Werf TS, Postma MJ.

Clin Ther. 2010 Aug;32(8):1517-32. doi: 10.1016/j.clinthera.2010.06.016.

PMID:
20728764
19.

The cost-effectiveness of pneumococcal conjugate vaccination in Australia.

Butler JR, McIntyre P, MacIntyre CR, Gilmour R, Howarth AL, Sander B.

Vaccine. 2004 Mar 12;22(9-10):1138-49.

PMID:
15003641
20.

Cost-effectiveness analysis of pneumococcal vaccination of adults and elderly persons in Belgium.

De Graeve D, Lombaert G, Goossens H.

Pharmacoeconomics. 2000 Jun;17(6):591-601.

PMID:
10977396
Items per page

Supplemental Content

Support Center